Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Low-Toxicity Anticancer Agent Proves Effective Against a Variety of Cancers

By BiotechDaily International staff writers
Posted on 08 Apr 2013
Researchers have discovered that the small chemical molecule FL118, a new formulation of a promising anticancer agent, is even more effective in controlling two kinds of cancer than an older version of the compound proved to be six months earlier. Further findings also suggest that the agent may successfully treat other solid tumors as well.

In their earlier research, a team led by Fengzhi Li, PhD, associate professor of oncology in Roswell Park Cancer Institute’s (RPCI; Buffalo, NY, USA) department of pharmacology and therapeutics, demonstrated that FL118 eliminated human colon and head-and-neck tumors in animal models without relapse but was limited in that it could be delivered only by intraperitoneal (IP) administration. This new study, to be published in the April 8, 2013, issue of the American Journal of Translational Research, compares the earlier formulation of the agent to a new version that can also be administered intravenously, adapting it to a much wider potential clinical application.

Comparing the antitumor effectiveness and therapeutic index, or relative toxicity, of FL118 in its new intravenous (IV) formulation with the earlier form, the researchers found that maximum tolerated dose increased three- to seven-fold, depending on dosing regimen. While the original formulation contained Tween 80 or polysorbate 80, a solvent typically included in drug formulations, the agent in its new composition is free of Tween 80, resulting in significantly lower toxicity.

FL118 is a targeted therapy that selectively inhibits the expression of four major cancer-survival gene products: survivin, XIAP, Mcl-1, and/or cIAP2. Whereas both studies assessed the compound’s effectiveness against models of head-and-neck and colon tumors, other research from Dr. Li’s lab suggests that mesothelioma, ovarian, and pancreatic cancers, and potentially other solid tumors, may also be good targets for treatment with FL118.

“This work represents a significant move forward,” noted Dr. Li, senior author on the study. “We’re targeting four of the most resilient and pervasive cancer survival mechanisms, and because the findings from preclinical testing have been so striking, we’re anxious to see FL118 tested in the clinical setting.”

The study’s findings were published online April 2, 2013, in the journal PLOS ONE.

Related Links:

Roswell Park Cancer Institute


Channels

Genomics/Proteomics

view channel
Image: Cancer cells, left, were pretreated with a drug that blocks the ERK signal, and right, without the pretreatment. Top cells are untreated, while the bottom ones are stimulated (Photo courtesy of the Weizmann Institute of Science).

Prevention of ERK Nuclear Translocation Blocks Cancer Proliferation in Animal Models

A team of cell biologists has shown that the cancer promoting effects of ERK dysregulation can be blocked by low molecular weight drugs that prevent translocation of this kinase from the cells' cytoplasm... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.